Skip to main content

Neuroradiology

The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.

The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.

In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.

Research lines

Quantitative analysis of MR images: image analysis and software development

This line is focused on the application of computer vision, image processing, pattern recognition, machine learning and fuzzy logic techniques to the analysis of MR images. Some areas of interest are the study of lesions, and iron quantification by means of advanced techniques such as QSM and SWI.

IP: Fco. Javier Aymerich Martínez

Research in Cerebrovascular Diseases

This research line is mainly focused on the assessment of intracranial aneurysms. This includes the role of several imaging techniques to predict the risk of future rupture. Other interests are to associate imaging changes with the pathophysiological mechanisms that underlie aneurysm formation and to optimize the imaging protocol used in clinical practice.

IP: Alex Rovira Cañellas

Synthetic Imaging: Assessing its value in healthcare practice

The aim of the line is to evaluate synthetic MR images compared to conventional images to consider its use in healthcare protocols.

IP: Fco. Javier Aymerich Martínez, Alex Rovira Cañellas

Projects

Desvelando los mecanismos que llevan al aumento irreversible de discapacidad en esclerosis múltiple mediante resonancia magnética multi-modal cuantitativa

IP: Carmen Tur Gomez
Collaborators: Jordi Rio Izquierdo, Oscar Persiva Morenza, Elena Huerga Núñez
Funding agency: Instituto de Salud Carlos III
Funding: 150040
Reference: PI21/01860
Duration: 01/01/2022 - 30/06/2026

Blog

News

Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga have been recognised in the listing.

Her nomination means that she will represent UPF in the national competition held annually.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

Rates

Magnetic Resonance image analysis